• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Catheters
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Injection Molding
    • Insert molding
    • Tools
  • Materials
    • Advanced Materials
    • Silicone
  • Research & Development
  • Suppliers

CereVasc wins FDA IDE approval to begin eShunt pilot study

February 8, 2022 By Danielle Kirsh

Cerevasc-LogoCereVasc today announced that it received an FDA investigational device exemption approval to begin a trial of the eShunt for normal pressure hydrocephalus.

The Boston-based company can initiate its pilot trial of the eShunt system in patients with normal pressure hydrocephalus (NPH). The eShunt device offers a minimally invasive treatment with the potential to result in benefits over the current gold-standard treatment.

“We are delighted the FDA has granted this IDE allowing CereVasc to commence an initial clinical study evaluating the use of the eShunt System in patients with NPH, a disorder estimated to affect more than 700,000 Americans. It’s an exciting and important milestone for CereVasc and we look forward to working closely with the study investigators to evaluate a new treatment option with the potential to benefit thousands of elderly hydrocephalus patients,” CEO Dan Levangie said in a news release.

Current treatment for hydrocephalus requires an invasive neurosurgical procedure, according to CereVasc. The company designed the device with an endovascularly implantable CSF count and associated delivery components that avoid the need for invasive surgery, general anesthesia, extended hospitalization and post-procedure pain management.

“We are excited about innovative therapies and the possibility of a minimally invasive treatment option for the management of hydrocephalus. This important trial could potentially benefit so many elderly patients disabled by this common neurologic disorder,” Hydrocephalus Association president and CEO Diana Gray said.

Filed Under: Implants, Shunts Tagged With: CereVasc

Primary Sidebar

DeviceTalks Tuesdays

DeviceTalks Tuesdays
MDO ad

Stay Current

Need Medical Tubing news in a minute?
We Deliver!

Medical Tubing + Extrusion newsletter get you caught up on all the mission critical news you need in medical tubing. Sign up today.

Enews Sign up

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

Medical Tubing & Extrusion

Subscribe to our e-newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS